Comparison
Epitalon vs. Semaglutid
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Metabolic
CAS no.
307297-39-8
910463-68-2
Molecular weight
390.35 g/mol
4113.6 g/mol
Half-life
0.3 h
165 h
Sequence
Ala-Glu-Asp-Glymodifiziertes GLP-1-Analogon (31 AS) mit C18-Fettsäure-LinkerMechanism of action
Epitalon
Postulated mechanisms include modulation of gene expression in pinealocytes, telomerase activation (observed in cell culture studies) and influence on melatonin synthesis. A defined primary receptor is not established; the mechanistic basis rests on in-vitro and animal data from the Khavinson group.
Semaglutid
Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
4
4
of which in humans
1
3
Effects recorded
4
3
Open conflicts
1
1
Documented adverse events
1
5